Share chart GlaxoSmithKline
Extended chart
Simple chart
About GlaxoSmithKline
GlaxoSmithKline plc вместе со своими дочерними компаниями занимается созданием, открытием, разработкой, производством и маркетингом фармацевтических продуктов, вакцин, безрецептурных лекарств и потребительских товаров для здоровья в Великобритании, США и на международном уровне. Он работает в четырех сегментах: фармацевтика, исследования и разработки в фармацевтике, вакцины и здравоохранение. more detailsIPO date | 1986-07-09 |
---|---|
ISIN | US37733W2044 |
Industry | Pharmaceuticals |
Sector | Health Care |
Валюта | usd |
Валюта отчета | gbp |
Див.доход ао | 4.15 |
Дивиденд ао | 0.4291 |
Сайт | https://www.gsk.com |
Цена ао | 37.37 |
Change price per day: | +2.05% (36.62) |
---|---|
Change price per week: | -0.3467% (37.5) |
Change price per month: | +7.88% (34.64) |
Change price per 3 month: | +3.6% (36.07) |
Change price per half year: | +6.44% (35.11) |
Change price per year: | -18.23% (45.7) |
Change price per 3 year: | -12.52% (42.72) |
Change price per 5 year: | +0.9727% (37.01) |
Change price per 10 year: | +14.77% (32.5598) |
Change price per year to date: | +9.81% (34.03) |
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
Dividend, % | Dividend | Result of period | Buy before | Register closing date | Payment before |
---|---|---|---|---|---|
1.02% | 0.393 | IV кв. 2024 | 19.02.2025 | 21.02.2025 | 10.03.2025 |
4.61% | 1.525 | III кв. 2024 | 13.11.2024 | 15.11.2024 | 02.12.2024 |
0.94% | 0.38 | II кв. 2024 | 14.08.2024 | 16.08.2024 | 02.09.2024 |
0.95% | 0.37 | I кв. 2024 | 14.05.2024 | 16.05.2024 | 31.05.2024 |
0.93% | 0.4 | IV кв. 2023 | 20.02.2024 | 22.02.2024 | 08.03.2024 |
0.96% | 0.33 | III кв. 2023 | 14.11.2023 | 16.11.2023 | 01.12.2023 |
0.94% | 0.34 | I кв. 2023 | 16.05.2023 | 18.05.2023 | 02.06.2023 |
0.96% | 0.33 | IV кв. 2022 | 21.02.2023 | 23.02.2023 | 10.03.2023 |
0.91% | 0.31 | III кв. 2022 | 15.11.2022 | 17.11.2022 | 02.12.2022 |
1.06% | 0.38 | II кв. 2022 | 16.08.2022 | 18.08.2022 | 02.09.2022 |
Transaction date | Date of disclosure | Insider | Type | Price | Volume | Quantity | Share before, % | Share after, % | Document |
---|---|---|---|---|---|---|---|---|---|
07.12.2023 | 30.01.2024 | GSK plc 10% Owner |
Purchase | 5 | 16 500 000 | 3300000 | 0 | 0.13 | link |
Institutions | Volume | Share, % |
---|---|---|
Dodge & Cox Inc | 69026793 | 3.33 |
FMR, LLC | 19366131 | 0.93 |
Fisher Asset Management, LLC | 15036881 | 0.73 |
Price (T.Rowe) Associates Inc | 12818958 | 0.62 |
JTC Employer Solutions Trusteee Ltd | 12340190 | 0.6 |
PRIMECAP Management Company | 12089370 | 0.58 |
Morgan Stanley | 8552173 | 0.41 |
Royal Bank of Canada | 8286487 | 0.4 |
Holocene Advisors, LP | 8224548 | 0.4 |
State Street Corporation | 7052990 | 0.34 |
ETF | Share, % | Profitability for 1 year, % | Dividends, % |
---|---|---|---|
SPDR Solactive United Kingdom ETF | 3.6 | 50.67 | 3.94 |
Pacer BioThreat Strategy ETF | 2.84213 | 14.04 | 1.65371 |
Barclays ETN+ FI Enhanced Europe 50 ETN Series C | 2.37 | 0 | 1.05 |
AAM S&P Developed Markets High Dividend Value ETF | 1.88686 | 11.63 | 7.65946 |
VanEck Morningstar Global Wide Moat ETF | 1.78619 | 58.27 | 2.44324 |
Pacific Global International Equity Income ETF | 1.72 | 0 | 2.68 |
FCF International Quality ETF | 1.64717 | 0.9917 | 2.88048 |
Nuveen Global Net Zero Transition ETF | 1.28105 | 16.12 | 1.77096 |
Knowledge Leaders Developed World ETF | 1.24702 | 14.17 | 1.90235 |
Credit Suisse FI Enhanced Europe 50 ETN | 0.93 | 49.45 | |
FlexShares International Quality Dividend Defensive Index Fund | 0.7774 | 13.37 | 5.72758 |
E-TRACS UBS Bloomberg CMCI Food ETN | 0.49648 | 17.97 | 2.94932 |
Fidelity New Millennium ETF | 0.33039 | -5.04 | 1.58241 |
IQ 500 International ETF | 0.32773 | 6.72 | 4.03885 |
VictoryShares Developed Enhanced Volatility Wtd ETF | 0.23444 | 11.06 | 3.73508 |
Head | Job title | Payment | Year of birth |
---|---|---|---|
Ms. Sarah Elton-Farr | Head of Investor Relations | N/A | |
Mr. James Ford | Senior VP & Group General Counsel of Legal & Compliance | N/A | |
Ms. Sally Jackson | Senior Vice President of Global Communications & CEO Office | N/A | |
Ms. Diana Conrad | Chief People Officer | N/A | |
Ms. Shobie Ramakrishnan | Chief Digital & Technology Officer | N/A | 1971 (54 years) |
Ms. Emma Natasha Walmsley | CEO & Director | 6.82M | 1969 (56 years) |
Mr. Tony Wood | Chief Scientific Officer and Head of R&D | N/A | |
Mr. David Simon Redfern BSc (Hons), CA | President of Corporate Development | N/A | 1966 (59 years) |
Mr. Philip C. Thomson | President of Global Affairs | N/A | |
Ms. Julie Belita Brown | CFO & Executive Director | 6.51M | 1962 (63 years) |
Address: United Kingdom, Brentford, 980 Great West Road - open in Google maps, open in Yandex maps
Website: https://www.gsk.com
Website: https://www.gsk.com